Literature DB >> 23769912

Rho GTPase signaling at the synapse: implications for intellectual disability.

Wei Ba1, Jori van der Raadt, Nael Nadif Kasri.   

Abstract

Intellectual disability (ID) imposes a major medical and social-economical problem in our society. It is defined as a global reduction in cognitive and intellectual abilities, associated with impaired social adaptation. The causes of ID are extremely heterogeneous and include non-genetic and genetic changes. Great progress has been made over recent years towards the identification of ID-related genes, resulting in a list of approximately 450 genes. A prominent neuropathological feature of patients with ID is altered dendritic spine morphogenesis. These structural abnormalities, in part, reflect impaired cytoskeleton remodeling and are associated with synaptic dysfunction. The dynamic, actin-rich nature of dendritic spines points to the Rho GTPase family as a central contributor, since they are key regulators of actin dynamics and organization. It is therefore not surprising that mutations in genes encoding regulators and effectors of the Rho GTPases have been associated with ID. This review will focus on the role of Rho GTPase signaling in synaptic structure/function and ID.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Intellectual disability; Rho GTPase; Synapse; Synaptic plasticity

Mesh:

Substances:

Year:  2013        PMID: 23769912     DOI: 10.1016/j.yexcr.2013.05.033

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  40 in total

Review 1.  Genetic studies in intellectual disability and related disorders.

Authors:  Lisenka E L M Vissers; Christian Gilissen; Joris A Veltman
Journal:  Nat Rev Genet       Date:  2015-10-27       Impact factor: 53.242

Review 2.  Mechanisms for spatiotemporal regulation of Rho-GTPase signaling at synapses.

Authors:  Joseph G Duman; Shalaka Mulherkar; Yen-Kuei Tu; Jinxuan X Cheng; Kimberley F Tolias
Journal:  Neurosci Lett       Date:  2015-05-21       Impact factor: 3.046

Review 3.  Intellectual disability and autism spectrum disorders: causal genes and molecular mechanisms.

Authors:  Anand K Srivastava; Charles E Schwartz
Journal:  Neurosci Biobehav Rev       Date:  2014-04-04       Impact factor: 8.989

Review 4.  RhoGTPases at the synapse: An embarrassment of choice.

Authors:  W Ba; N Nadif Kasri
Journal:  Small GTPases       Date:  2016-08-05

5.  PAK1 regulates inhibitory synaptic function via a novel mechanism mediated by endocannabinoids.

Authors:  Shuting Xia; Zikai Zhou; Zhengping Jia
Journal:  Small GTPases       Date:  2016-09-20

6.  Expression of p21-activated kinases 1 and 3 is altered in the brain of subjects with depression.

Authors:  Beata Fuchsova; Anabel Alvarez Juliá; Hooriyah S Rizavi; Alberto Carlos Frasch; Ghanshyam N Pandey
Journal:  Neuroscience       Date:  2016-07-27       Impact factor: 3.590

7.  Pharmacological Rescue of Hippocampal Fear Learning Deficits in Fragile X Syndrome.

Authors:  Luis A Martinez; Maria Victoria Tejada-Simon
Journal:  Mol Neurobiol       Date:  2017-11-11       Impact factor: 5.590

8.  Regulation of AMPA receptor subunit GluA1 surface expression by PAK3 phosphorylation.

Authors:  Natasha K Hussain; Gareth M Thomas; Junjie Luo; Richard L Huganir
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

9.  Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for Rett syndrome.

Authors:  Bianca De Filippis; Paola Nativio; Alessia Fabbri; Laura Ricceri; Walter Adriani; Enza Lacivita; Marcello Leopoldo; Francesca Passarelli; Andrea Fuso; Giovanni Laviola
Journal:  Neuropsychopharmacology       Date:  2014-05-09       Impact factor: 7.853

10.  Microcephaly-dystonia due to mutated PLEKHG2 with impaired actin polymerization.

Authors:  Simon Edvardson; Haibo Wang; Talya Dor; Osamah Atawneh; Barak Yaacov; Jutta Gartner; Yuval Cinnamon; Songhai Chen; Orly Elpeleg
Journal:  Neurogenetics       Date:  2015-11-17       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.